MANNITOL Side Effects

6835353-8 | Blood Sodium Decreased, Cardiac Arrest, Cardiac Disorder, Hyperkalaemia, Hypocalcaemia, Hypokinesia, Ventricular Fibrillation, Ventricular Tachycardia
on Jun 17, 2010 Male patient from UNITED STATES , 41 years of age, was diagnosed with intracranial pressure increased and was treated with Mannitol (View Usage). Patient experienced the following unwanted or unexpected effects: blood sodium decreased, cardiac arrest (What is cardiac arrest?), cardiac disorder, hyperkalaemia, hypocalcaemia, hypokinesia, ventricular fibrillation, ventricular tachycardia. Mannitol dosage: . During the same period patient was treated with ANESTHESIA (View Anesthesia Review and Anesthesia Label ).

6818736-1 | Acidosis, Renal Failure Acute
Patient was taking Mannitol (View Usage). Patient had the following side effects: acidosis, renal failure acute on Jun 15, 2010 from JAPAN Additional patient health information: Male patient , 56 years of age, weighting 159.6 lb, was diagnosed with abnormal sensation in eye and. Mannitol dosage: . During the same period patient was treated with ACETAZOLAMIDE (View Acetazolamide Review and Acetazolamide Label ).

6649999-3 | Abdominal Discomfort, Diverticulitis
Adverse event was reported on Mar 24, 2010 by a Female patient taking Mannitol (View Usage) (Dosage: 1x Day Oral) was diagnosed with blood pressure (What is blood pressure?) and. Location: UNITED STATES , 66 years of age, weighting 135.0 lb, After Mannitol was administered, patient had the following side effects: abdominal discomfort, diverticulitis. Patient was hospitalized.

5813576-4 | Brain Oedema, Hyponatraemia, Mental Status Changes
on Jul 16, 2008 Male patient from UNITED STATES , 48 years of age, was treated with Mannitol (View Usage). Patient experienced the following unwanted or unexpected effects: brain oedema, hyponatraemia, mental status changes. Mannitol dosage: See Above. Patient was hospitalized.


5414757-4 | Maculopathy
on Aug 03, 2007 Female patient from UNITED STATES , 66 years of age, was diagnosed with blood brain barrier defect, lymphoma (What is lymphoma?) and was treated with Mannitol (View Usage). Patient had the following side effects: maculopathy. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5414756-2 | Maculopathy
Patient was taking Mannitol (View Usage). After Mannitol was administered, patient had the following side effects: maculopathy on Aug 03, 2007 from UNITED STATES Additional patient health information: Female patient , 66 years of age, was diagnosed with blood brain barrier defect, central nervous system lymphoma and. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5414755-0 | Maculopathy, Visual Disturbance
Adverse event was reported on Aug 03, 2007 by a Female patient taking Mannitol (View Usage) (Dosage: 2 Days Once Monthly, Intra-arterial) was diagnosed with blood brain barrier defect, lymphoma (What is lymphoma?) and. Location: UNITED STATES , 65 years of age, Patient experienced the following unwanted or unexpected effects: maculopathy, visual disturbance. During the same period patient was treated with METHOTREXATE (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5414754-9 | Blood Brain Barrier Defect, Central Nervous System Lymphoma, Maculopathy
on Aug 03, 2007 Female patient from UNITED STATES , 57 years of age, was diagnosed with blood brain barrier defect, central nervous system lymphoma and was treated with Mannitol (View Usage). Patient had the following side effects: blood brain barrier defect, central nervous system lymphoma, maculopathy. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5414753-7 | Maculopathy
on Aug 03, 2007 Female patient from UNITED STATES , 54 years of age, was diagnosed with central nervous system lymphoma and was treated with Mannitol (View Usage). After Mannitol was administered, patient had the following side effects: maculopathy. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5414743-4 | Maculopathy
Patient was taking Mannitol (View Usage). Patient experienced the following unwanted or unexpected effects: maculopathy on Aug 03, 2007 from UNITED STATES Additional patient health information: Female patient , 34 years of age, was diagnosed with blood brain barrier defect, lymphoma (What is lymphoma?) and. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5414742-2 | Maculopathy
Adverse event was reported on Aug 03, 2007 by a Female patient taking Mannitol (View Usage) (Dosage: 2 Days Once Monthly, Intra-arterial) was diagnosed with blood brain barrier defect, central nervous system lymphoma and. Location: UNITED STATES , 73 years of age, Patient had the following side effects: maculopathy. During the same period patient was treated with METHOTREXATE (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Review and Methotrexate Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5404985-6 | Maculopathy
on Jul 22, 2007 Female patient from UNITED STATES , 34 years of age, was diagnosed with nervous system disorder, central nervous system lymphoma and was treated with Mannitol (View Usage). After Mannitol was administered, patient had the following side effects: maculopathy. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE SODIUM (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Sodium Review and Methotrexate Sodium Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE ) (View Etoposide Phosphate (etoposide Phosphate ) Review and Etoposide Phosphate (etoposide Phosphate ) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5404984-4 | Maculopathy
on Jul 22, 2007 Female patient from UNITED STATES , 73 years of age, was diagnosed with brain operation, central nervous system lymphoma and was treated with Mannitol (View Usage). Patient experienced the following unwanted or unexpected effects: maculopathy. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE SODIUM (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Sodium Review and Methotrexate Sodium Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE ) (View Etoposide Phosphate (etoposide Phosphate ) Review and Etoposide Phosphate (etoposide Phosphate ) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5404982-0 | Macular Oedema, Maculopathy, Visual Acuity Reduced
Patient was taking Mannitol (View Usage). Patient had the following side effects: macular oedema, maculopathy, visual acuity reduced on Jul 22, 2007 from UNITED STATES Additional patient health information: Female patient , 66 years of age, was diagnosed with nervous system disorder, central nervous system lymphoma and. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE SODIUM (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Sodium Review and Methotrexate Sodium Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE ) (View Etoposide Phosphate (etoposide Phosphate ) Review and Etoposide Phosphate (etoposide Phosphate ) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5404978-9 | Macular Oedema, Maculopathy, Visual Disturbance
Adverse event was reported on Jul 22, 2007 by a Female patient taking Mannitol (View Usage) (Dosage: 2 Days Once Monthly, Intra-arterial) was diagnosed with blood brain barrier defect, central nervous system lymphoma and. Location: UNITED STATES , 66 years of age, After Mannitol was administered, patient had the following side effects: macular oedema, maculopathy, visual disturbance. During the same period patient was treated with METHOTREXATE SODIUM (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Sodium Review and Methotrexate Sodium Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE ) (View Etoposide Phosphate (etoposide Phosphate ) Review and Etoposide Phosphate (etoposide Phosphate ) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5404977-7 | Maculopathy
on Jul 22, 2007 Female patient from UNITED STATES , 65 years of age, was diagnosed with nervous system disorder, central nervous system lymphoma and was treated with Mannitol (View Usage). Patient experienced the following unwanted or unexpected effects: maculopathy. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE SODIUM (5000 Mg/m2, 1 In 1 M, Intra-arterial) (View Methotrexate Sodium Review and Methotrexate Sodium Label ), CYCLOPHOSPHAMIDE (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5404976-5 | Maculopathy
on Jul 22, 2007 Female patient from UNITED STATES , 57 years of age, was diagnosed with brain operation, central nervous system lymphoma and was treated with Mannitol (View Usage). Patient had the following side effects: maculopathy. Mannitol dosage: 2 Days Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE SODIUM INJECTION (METHOTREXATE) (5000 Mg/m2, 1 In 1 M; Intra-arterial) (View Methotrexate Sodium Injection (methotrexate) Review and Methotrexate Sodium Injection (methotrexate) Label ), CYCLOPHOSPHAMIDE ( 2D CYCLOPHOSPHAMIDE) (View Cyclophosphamide ( -2d Cyclophosphamide) Review and Cyclophosphamide ( -2d Cyclophosphamide) Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5404974-1 | Maculopathy
Patient was taking Mannitol (View Usage). After Mannitol was administered, patient had the following side effects: maculopathy on Jul 22, 2007 from UNITED STATES Additional patient health information: Female patient , 54 years of age, was diagnosed with nervous system disorder, central nervous system lymphoma and. Mannitol dosage: 2, Days; Once Monthly, Intra-arterial. During the same period patient was treated with METHOTREXATE SODIUM INJECTION (METHOTREXATE) (5000 Mg/m2, 1 In 1 M; Intra-arterial) (View Methotrexate Sodium Injection (methotrexate) Review and Methotrexate Sodium Injection (methotrexate) Label ), CYCLOPHOSPHAMIDE ( 2D CYCLOPHOSPHAMIDE) (View Cyclophosphamide (-2d Cyclophosphamide) Review and Cyclophosphamide (-2d Cyclophosphamide) Label ), ETOPOSIDE PHOSPHATE (ETOPOSIDE PHOSPHATE) (View Etoposide Phosphate (etoposide Phosphate) Review and Etoposide Phosphate (etoposide Phosphate) Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ).

5152522-6 | Disease Progression, Malignant Neoplasm Progression, Thrombocytopenia, Tumour Lysis Syndrome
Adverse event was reported on Oct 13, 2006 by a Male patient taking Mannitol (View Usage) (Dosage: 2.5 Mg, Other) was diagnosed with non-hodgkin's lymphoma and. Location: UNITED STATES , 64 years of age, weighting 141.1 lb, Patient experienced the following unwanted or unexpected effects: disease progression, malignant neoplasm progression, thrombocytopenia, tumour lysis syndrome. During the same period patient was treated with GEMZAR (1955 Mg, Other) (View Gemzar Review and Gemzar Label ), CISPLATIN (56 Mg/m2, Other) (View Cisplatin Review and Cisplatin Label ), DEXAMETHASONE TAB (20 Mg, Other) (View Dexamethasone Tab Review and Dexamethasone Tab Label ).

4956318-7 | Condition Aggravated, Electrocardiogram Qrs Complex Prolonged, Electrocardiogram T Wave Peaked, Hyperkalaemia, Hyponatraemia, Metabolic Acidosis
on Mar 13, 2006 Male patient from JAPAN , 15 years of age, weighting 119.0 lb, was diagnosed with reduction of increased intracranial pressure and was treated with Mannitol (View Usage). Patient had the following side effects: condition aggravated, electrocardiogram qrs complex prolonged, electrocardiogram t wave peaked, hyperkalaemia, hyponatraemia, metabolic acidosis. Mannitol dosage: 300 Ml, Intravenous Drip. During the same period patient was treated with LACTATE RINGER SOLUTION (View Lactate Ringer Solution Review and Lactate Ringer Solution Label ), SEVOFLURANE (View Sevoflurane Review and Sevoflurane Label ), FENTANYL CITRATE (View Fentanyl Citrate Review and Fentanyl Citrate Label ), VECURONIUM BROMIDE (View Vecuronium Bromide Review and Vecuronium Bromide Label ).

4919977-0 | Hyperkalaemia, Metabolic Acidosis
on Feb 08, 2006 Male patient from JAPAN , 15 years of age, was treated with Mannitol (View Usage). After Mannitol was administered, patient had the following side effects: hyperkalaemia, metabolic acidosis. Mannitol dosage: Infusion.